ACOTEC-B (06669.HK): Expects Interim Results to Swing to Net Loss of up to RMB 80.9 Million on Termination of U.S. Clinical Project

NewTimeSpace News: On 12 August 2026, Acotec Scientific Holdings Limited (stock code: 06669) issued a profit warning, expecting a net loss of not more than RMB 80.9 million for the six months ended 30 June 2026, compared with a net profit of approximately RMB 88.6 million for the six months ended 30 June 2025, turning from profit to loss.

The announcement attributed the loss mainly to the termination of the U.S. clinical trial project for the AcoArt Litos paclitaxel-coated PTA balloon catheter, resulting in a one-off non-cash impairment loss (being the capitalized R&D expenses of the clinical project) and a one-off provision for expenses related to the termination, totaling approximately RMB 150.8 million. Following management's review, given that changes in future product pipeline and local U.S. market dynamics may limit the product's profitability, the Group terminated the clinical project, as management considers allocating resources to other future product pipelines commercially more desirable, and is exploring new overseas pipeline with its commercial partners.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.